Protocol to Obtain Blood Samples for Leukemia Research

NCT00889031 | Completed DMC

• 1 other identifier: D0905
• Study Type: observational
• Target: 187
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to collect a blood sample in patients with Chronic Lymphocytic Leukemia (CLL).

Conditions

Chronic Lymphocytic Leukemia

Keywords

CLL

Outcome Measures

Primary Outcomes (1)

• To determine the frequency with which CLL cells incubated ex vivo with vincristine undergo rapid interphase apoptosis.

  2 Years

Secondary Outcomes (1)

• To determine whether suppression or inhibition of BCL2 family members can acutely sensitize CLL cells to vincristine.

  2 Years

Study Arms (1)

No Treatment

Other: No Intervention

Interventions

No Intervention OTHER

Patients with Chronic Lymphocytic Leukemia (CLL)

No Treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center

You may qualify if:

• Patients undergoing routine blood draws as part of their ongoing follow-up for Chronic Lymphocytic Leukemia (CLL) at the Norris Cotton Cancer Center of DHMC.

Sponsors & Collaborators

• Dartmouth-Hitchcock Medical Center: lead

Study Sites (1)

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States

Location

Related Publications (3)

• Stadheim TA, Xiao H, Eastman A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res. 2001 Feb 15;61(4):1533-40.

  PMID: 11245462 BACKGROUND

• Vilpo JA, Koski T, Vilpo LM. Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol. 2000 Dec;65(6):370-8. doi: 10.1034/j.1600-0609.2000.065006370.x.

  PMID: 11168494 BACKGROUND

• Kivekas I, Vilpo L, Vilpo J. Relationships of in vitro sensitivities tested with nine drugs and two types of irradiation in chronic lymphocytic leukemia. Leuk Res. 2002 Nov;26(11):1035-41. doi: 10.1016/s0145-2126(02)00050-4.

  PMID: 12363473 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

10cc of peripheral blood.

MeSH Terms

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Condition Hierarchy (Ancestors)

Leukemia, B-Cell; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Christopher H Lowrey, MD

  Dartmouth-Hitchcock Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Medicine and of Pharmacology and Toxicology

Study Record Dates

• First Submitted: April 24, 2009
• First Posted: April 28, 2009
• Study Start: April 1, 2009
• Primary Completion: March 9, 2018
• Study Completion: March 9, 2018
• Last Updated: April 7, 2020

Record last verified: 2020-04

Locations

US (1)